文献速递甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

分化型甲状腺癌放射性碘治疗中的争议

Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer.
PubMed 文献 · Semin Nucl Med · 2023-02-20

本文综述分化型甲状腺癌(DTC)放射性碘(I-131)治疗40年来标准化方案的争议,涉及低危患者是否需I-131、消融活度选择、剂量学方法优化及长期安全性等未决问题,并指出精准肿瘤学时代基于基因谱的个体化治疗是核医学的挑战与机遇。

要点

  • 标准化I-131方案长期服务多数DTC患者,但低危患者是否需治疗及如何识别存疑。
  • 多项临床试验质疑I-131消融活度选择及低危患者治疗指征。
  • 剂量学方法尚未在正式临床试验中显示改善结局。

核心结论

  • DTC的I-131治疗标准化方案40年来变化不大,多数患者获益良好。
  • 近年对低危患者是否需I-131及如何识别需强化治疗者存在疑问。
  • 多项临床试验质疑I-131消融活度选择及低危患者治疗指征,且I-131长期安全性仍有疑问。
  • 剂量学方法目前尚未在正式临床试验中显示改善结局。
  • 精准肿瘤学时代要求从标准治疗转向基于基因谱的个体化治疗,对核医学既是挑战也是机遇。

研究设计与样本

  • 本文为综述,检索范围及方法原文未报告。

主要发现

  • 标准化I-131治疗在过去40年变化不大,多数DTC患者获得良好服务。
  • 近期对部分低危患者采用标准化方案存在疑问,包括如何识别这些患者及哪些患者可能需要更强化治疗。
  • 多项临床试验对DTC治疗范式提出质疑,涉及I-131消融应使用何种活度及哪些低危患者应接受I-131治疗。
  • I-131的长期安全性仍存疑问。
  • 剂量学方法目前尚未在正式临床试验中显示改善结局。

关键数值与推荐

  • 原文未报告具体推荐条款、剂量、阈值或统计数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of radioiodine (I-131) in the management of patients suffering differentiated thyroid cancer (DTC) has changed little in the past 40 years. The use of a standardized approach has served the majority of patients well over that time. However, there have been recent doubts concerning this approach in some low risk patients and if so, how can these patients recognized and which patients who may need more intensive treatment. A number of clinical trials have questioned the paradigms used in the treatment of DTC including what activity of I-131 should be used for ablation and which low risk patients should be treated with I-131 especially as there remains some doubts as to the long-term safety of I-131. Should a dosimetric approach be used to optimize the use of I-131 even though at present this approach has not been shown to improve outcomes in a formal clinical trial. The era of precision oncology represents a challenge and opportunity to nuclear medicine with a move away from a regime of standard care to one of highly individualized care based on the genetic profiling of the patient and their cancer. The treatment of DTC with I-131 is about to become very interesting.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Buscombe J. Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer. Semin Nucl Med. 2023. PMID: 36813671. doi:10.1053/j.semnuclmed.2023.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。